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Abstract— Non-alcoholic fatty liver disease (NAFLD) is the most common cause of
chronic liver disease. Inflammatory pathways contribute to disease pathogenesis; however,
regulation of the underlying mechanism is not completely understood. IL-1β, a pro-
inflammatory cytokine, participates in the development and progression of NAFLD. To
become bioactive, IL-1β requires enzymatic processing. Mechanisms that activate IL-1β
include the classical NLRP3 inflammasome-caspase-1 and the neutrophil serine proteases,
neutrophil elastase, and proteinase-3. Several studies have shown that both caspase-1 and the
neutrophil serine proteases are important for NAFLD development. However, it is unknown
whether these pathways interact and if they have a synergistic effect in promoting NAFLD. In
the present study, we developed a novel and unique mouse model by intercrossing caspase-1/
11 knockout mice with neutrophil elastase/proteinase-3 double knockout mice. Subsequently,
these mice were examined regarding the development of high-fat diet–induced NAFLD. Our
results show that mice deficient in caspase-1, neutrophil elastase, and proteinase-3 were
protected from developing diet-induced weigh gain, liver steatosis, and adipose tissue
inflammation when compared with controls. We conclude that pathways that process pro-
IL-1β to bioactive IL-1β play an important role in promoting the development of NAFLD
and obesity-induced inflammation. Targeting these pathways could have a therapeutic po-
tential in patients with NAFLD.
KEYWORDS: obesity; inflammation; neutrophil serine proteases; IL-1 beta.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10753-020-01190-4) contains supplementary ma-
terial, which is available to authorized users.
1 Department of Internal Medicine, Radboud Institute for Molecular Life
Sciences (RIMLS), Radboud University Medical Center, Geert Groote-
plein Zuid 8, 6525 GA Nijmegen, The Netherlands
2 Department of Medical Genetics, Iuliu Hatieganu University of Medicine
and Pharmacy, Pasteur Street, Number 6, 400349 Cluj-Napoca, Romania
3 Nutrition, Metabolism and Genomics Group, Division of Human Nutri-
tion, Wageningen University, Droevendaalsesteeg 4, 6708
PB Wageningen, The Netherlands
4 Department of Immunology, St Jude Children’s Research Hospital, Mem-
phis, TN 38105, USA
5 Institute for Clinical Chemistry and Laboratory Medicine, University
Clinic Carl-Gustav-Carus, Technische Universität Dresden, Fetscherstraße
74, 01307 Dresden, Germany
6 Paul Langerhans Institute Dresden, Helmholtz Zentrum München, Uni-
versity Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden,
Tatzberg 47, 01307 Dresden, Germany
7German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany
8 R&D Department, Hycult Biotechnology, Frontstraat 2A, 5405 PB Uden,
The Netherlands
9 To whom correspondence should be addressed at Department of Medical
Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Pasteur
Street, Number 6, 400349 Cluj-Napoca, Romania. E-mail: andreea-
manuela.mirea@radboudumc.nl
0360-3997/20/0000-0001/0 # 2020 The Author(s)
Inflammation (# 2020)
DOI: 10.1007/s10753-020-01190-4
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the
most common cause of chronic liver disease world-
wide [1]. It is strongly associated with obesity and
insulin resistance [2]. NAFLD ranges from mild liver
steatosis to severe liver steatosis accompanied by
hepatic inflammation, in which case the term non-
alcoholic steatohepatitis (NASH) is used. NASH can
further progress into liver fibrosis, cirrhosis, and even
hepatocellular carcinoma [3]. Although the disease is
frequent, the underlying mechanisms responsible for
its development and progression are not fully under-
stood. During the last few years, it became apparent
that inflammation is an important factor in the path-
ogenesis of NAFLD. The pro-inflammatory cytokine
IL-1β has a key role in the development and pro-
gression of NAFLD being involved in all the stages
ranging from liver steatosis to NASH and fibrosis
[4]. IL-1β is produced as an inactive protein and
needs proteolytic cleavage in order to become bioac-
tive. Several mechanisms are able to activate IL-1β
in NAFLD. Most studied for its role in NAFLD and
another metabolic disturbance is the classical NLRP3
inflammasome activation pathway [5–8]. Upon stim-
ulation, the NLRP3 protein complex assembles and
cleaves pro-caspase-1 to active caspase-1. In turn,
caspase-1 activates the pro-inflammatory cytokines
IL-1β and IL-18 leading to induction and/or prolon-
gation of inflammation [9] (Fig. 1). Several studies
have shown that the NLRP3 inflammasome and
caspase-1 are directly involved in NAFLD by pro-
moting the development of inflammation and fibrosis
and also indirectly by promoting associated metabolic
disturbances such as adipose tissue inflammation and
insulin resistance [6, 7, 10–12]. However, next to the
NLRP3 inflammasome-caspase-1 pathway, also neu-
trophil serine proteases (NSPs), such as proteinase 3
(PR3) and neutrophil elastase (NE), are able to pro-
cess cytokines to their bioactive forms. These neutro-
phil serine proteases are stored in the azurophilic
granules of neutrophils. Upon neutrophil activation,
these proteases are released and activate several cyto-
kines, such as IL-1β, IL-18, and TNF [13], either in
the neutrophil cytosol or in the extracellular compart-
ment [14] (Fig. 1). When extracellular, NSPs are
inhibited by alpha-1 antitrypsin (AAT), an acute
phase protein mainly synthesized in the liver [15],
thereby attenuating the inflammatory response. Re-
cently, several studies have shown that these NSPs
are involved in the development of metabolic dis-
e a s e s s u ch a s T2DM and NAFLD in an
inflammasome-independent manner. For example,
Mansuy-Aubert and collaborators have shown that
NE knockout mice are protected from developing
obesity-induced liver steatosis and insulin resistance
[16]. Moreover, they have shown that there is an
imbalance between NE serum activity and AAT se-
rum concentrations in obese individuals [16]. Consis-
tent with these results, Zang and collaborators have
shown an imbalance between NE and AAT serum
concentrations in individuals with biopsy-diagnosed
NAFLD when compared with healthy individuals.
They calculated rather good sensitivity and specificity
scores for the NE/AAT ratio in order to predict the
advanced stages of the disease [17]. Our group has
recently shown that, additionally to NE, also PR3
plays an important role in the development of
obesity-induced NAFLD and insulin resistance in a
mouse model for obesity-induced NAFLD [18]. Fur-
thermore, we have shown that administering human
AAT protects against disease development in a
mouse model of obesity-induced NAFLD [18].
These studies clearly indicate that both inflammasome-
dependent and independent pathways are involved in the
development of metabolic conditions. The aim of this study
was to investigate the synergistic effect of NSPs and the
inflammasome/caspase-1 on the development of NAFLD.
To do so, we developed a unique knockout mouse model
deficient in caspase-1 (Casp1), PR3 (Prtn3), and NE
(Elane), in which the development of diet-induced NAFLD
was assessed.
MATERIAL AND METHODS
Animals
Caspase-1 (Casp1) knockout mice, which also miss
caspase-11 (Casp11) [19] and NE/PR3 (Prtn3/Elane)
knockout mice, were developed as previously described
[20, 21] and intercrossed to obtain a quadruple knockout
mice (Casp1/Casp11/NE/PR3). Genotyping of the mice
was performed as previously described [19, 20]. Age-
matched wild-type (WT) C57BL/6J mice were used as
controls.
Animals were single-caged in a pathogen-free facility
with a 12:12-h light-dark cycle and water and food ad
libitum. All mice were 10- to 12-week-old males at the
start of diet intervention. All interventions were approved
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by the Ethics Committee for Animal Experiments at Wage-
ningen University. All experiments were conducted in
accordance with the EU Directive 2010/63 for animal
experiments.
Diet Intervention
Both male Casp1/Casp11/NE/PR3 knockout and
male WT control mice were divided in groups of 12 ani-
mals and given a low-fat diet (LFD) or a high-fat diet
(HFD) with 10%, or 45% of the energy derived from fat,
respectively (D12450B, D12451; Research Diets), for
16 weeks. Body weight and food intake were measured
weekly.
Insulin tolerance test (ITT) and oral glucose tolerance
test (oGTT) were performed to assess glycemic control.
Mice were fasted 5 h before intraperitoneal administration
of insulin (0.75 U/kg) or glucose administration (2 g/kg) by
oral gavage. Blood samples were obtained by tail-cut and
glucose concentration was measured at baseline and after
15, 30, 45, 60, 90, and 120 min using an Accu-Chek
g lucose me te r (Roche Diagnos t i c s , A lmere ,
The Netherlands).
Plasma Measurements
At the end of the study, blood was collected in
heparin-coated tubes and centrifuged to collect plasma.
Triglycerides (TG) and total cholesterol (TC) were deter-
mined using a liquicolor kit from Instruchemie (Delfzijl,
The Netherlands). Free fatty acids (FFAs) were measured
using the NEFA-C kit from Wako Diagnostics (Instruche-
mie, Delfzijl, The Netherlands). Glucose was measured
enzymatically following manufacturer’s protocols (Liqui-
color, Human GmbH, Wiesbaden, Germany). Adiponectin
and leptin were measured by ELISA using manufacturer’s
protocol (R&D Systems, Minneapolis, USA). All samples
were measured in a single replicate. For each run, in-house
controls were included in order to test for reproducibility
and batch-to-batch variation.
Liver and Gonadal Adipose Tissue (gWAT) Histology
Liver and gWAT were isolated, formalin-fixed,
and paraffin-embedded before staining. Liver sections
of 5 μm were cut and stained with hematoxylin and
eosin. Liver steatosis was determined by assessing
the percentage of cells containing lipid droplets per
field. Four fields were analyzed per sample. We
noted with “0” the absence of liver steatosis. Steato-
sis degrees were defined as follows: first degree
(noted with “1”)—between 5 and 33% of cells per
field contained lipid droplets; second degree (noted
with “2”)—between 33 and 66% of cells per field
contained lipid droplets; third degree (noted with
Fig. 1. The role of IL-1β activation pathways in NAFLD. Pro-inflammatory cytokines contribute to NAFLD development from liver steatosis to NASH and
fibrosis by activating sterile inflammation in the liver. Some of these cytokines such as IL-1β and IL-18 are secreted as inactive and need proteolytic cleavage
in order to become active. Two mechanisms responsible for IL-1 cytokine activation are represented by the NLRP3 inflammasome-caspase-1 protein
complex and the neutrophil serine proteases PR3 and NE. Additionally to IL-1β and IL-18, PR3 and NE are able to activate membrane-bound TNF.
Activating pro-inflammatory NLRP3 inflammasome-caspase-1 complex and the neutrophil serine proteases also contributes to NAFLD development and
progression. IL-1β, interleukin-1β; IL-18, interleukin-18; NASH, non-alcoholic steatohepatitis; NE, neutrophil elastase; PR3, proteinase-3; Pro-IL-1β, pro-
interleukin-1β; Pro-IL-18, pro-interleukin-18; TNF, tumor necrosis factor.
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“3”)—more than 66% of cells per field contained
lipid droplets [22]. Gonadal adipose tissue sections
of 8 μm were cut and stained by DAB (3′3-diami-
nobenzidine) technique with an F4/80 antibody (Bio-
Rad, Veenendaal, The Netherlands). Crown-like struc-
tures and adipocytes were counted in four images per
sample.
Liver Triglycerides Assessment
To measure liver triglycerides, we prepared 20% liver
homogenates using a buffer with 0.25 M saccharose,
20 mM Tris-HCL, 1 mM dithiothreitol (DTT), and 1%
Triton X-100 at a pH of 7.4. Triglycerides were measured
using a liquicolor kit from Instruchemie (Delfzijl,
The Netherlands). All samples were measured in a single
replicate. For each run, in-house controls were included in
order to test for reproducibility and batch-to-batch
variation.
RNA Isolation and Gene Expression Analysis
Total RNA was isolated from liver and gWAT
using TRIzol reagent (Life Technologies Europe BV,
Bleiswijk, The Netherlands) and quantified with a
NanoDrop spectrophotometer (NanoDrop Technolo-
gies, Wilmington, USA). A total of 1 μg of RNA
was reverse-transcribed to cDNA using an iScript
mix (Bio-Rad Laboratories) and gene expression
analysis was done by quantitative polymerase chain
reaction (qPCR) using SYBR green–based quantifica-
tion (Applied Biosystems, Foster City, CA, USA).
Primers were developed with Primer3 (Primer3 Input
(version 0.4.0) or selected from Harvard Primer Bank
(https://pga.mgh.harvard.edu/primerbank/).The gene
36b4 was used as an endogenous control. Differences
in expression were calculated using the 2ΔΔCt
method [23]. A list with our primers’ sequence is
available in Supplementary Table 1. All samples
were measured in duplicates.
Statistical Analysis
Data are represented as mean ± SEM. Statistical anal-
ysis and graphs were performed using Graphpad Prism
5.03 (La Jolla, USA). Data were analyzed using, as appro-
priate, the Student t test or one-way ANOVA with Tukey
post hoc test. To examine the effects of both diet and
genotype in our murine model, we used a two-way
ANOVA with Bonferroni post hoc test. A p value < 0.05
was considered significant.
RESULTS
Deficiency in IL-1β Activation Pathways Protects
Against HFD-Induced Obesity
To explore the combined effect of NSPs and the
inflammasome/caspase-1 pathway on NAFLD disease de-
velopment, Casp1/Casp11/NE/PR3 knockout mice and
WT control mice were fed a LFD or a HFD for 16 weeks.
Before the start of the diet intervention, no differences in
bodyweight were observed between the groups. As
expected, bodyweight of the WT mice group increased
significantly after HFD (Fig. 2a). In the Casp1/Casp11/
NE/PR3 knockout mice, weight gain was significantly less
after HFDwhen compared with theWT group (p < 0.0001)
and was similar to the weight gain observed in the WTand
the Casp1/Casp11/NE/PR3 mice fed a LFD (Fig. 2a). No
differences in food intake were observed between Casp1/
Casp11/NE/PR3 knockout mice and WT mice fed a HFD
(Fig. 2b). Mice that received a HFD had a significant
higher gWAT weight when compared with mice fed the
LFD (1.81 ± 0.42mg versus 0.74 ± 0.27mg, p < 0.0001 for
WT mice and 0.86 ± 0.39 mg versus 0.49 mg ± 0.19 mg,
p < 0.05 for Casp1/Casp11/NE/PR3 knockout mice) (Fig.
2c). No differences in liver, spleen, and pancreas weight
were observed between the four mice groups. Notably, WT
mice fed a HFD had a higher gWAT weight than Casp1/
Casp11/NE/PR3 knockout mice fed the same diet (1.81 ±
0.42 mg versus 0.86 ± 0.39 mg; p < 0.0001). These results
indicate that Casp1/Casp11/NE/PR3 knockout mice are
protected from diet-induced obesity.
Casp1/Casp11/NE/PR3 Knockout Mice Have Lower
Circulating Lipid Levels
Circulating lipid levels are increased in obesity and
are associated with cardiovascular and NAFLD outcome
[24]. Therefore, we measured plasma lipid levels in the
different genotypes to assess dyslipidemia (Fig. 2d–f). No
differences in plasma triglycerides levels were observed
between WT mice and 4ko mice, regardless of the type of
diet. Interestingly, Casp1/Casp11/NE/PR3 knockout mice
fed a HFD had significantly lower circulating free fatty
acid levels (0.54 ± 0.16 mmol/L versus 0.7 ± 0.17 mmol/L;
p = 0.02) (Fig. 2e) and lower circulating cholesterol levels
(2.36 ± 0.43 mmol/L versus 3.32 ± 0.84 mmol/L; p < 0.01)
(Fig. 2f) when compared with WT mice fed the same diet.
Hence, Casp1/Casp11/NE/PR3 knockout mice had lower
circulating lipid levels when compared with the WT
controls.
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Casp1/Casp11/NE/PR3 Knockout Mice Are Protected
from Developing Obesity-Induced Liver Steatosis
Liver steatosis was assessed in liver slides stained with
hematoxylin and eosin (H&E). Non-quantified visual inspec-
tion of H&E-stained liver sections showed that lipid droplets
were much more abundant in the livers of WT mice when
compared with those of the knockout mice (Fig. 3a). In order
to investigate the effect of diet intervention in the liver, we
further quantified the degree of liver steatosis in the different
mouse groups by assessing the percentage of cells containing
lipid droplets per field in the stained liver slides. Nine of the
Casp1/Casp11/NE/PR3 knockout mice fed a HFD (nine
knockout mice versus four WT mice) did not develop liver
Fig. 2. Phenotype at the end of the diet. WT, wild-type mice; 4ko, Casp1/Casp11/NE/PR3 knockout mice. a Gain in body weight during the HFD/LFD
intervention. b Weekly food intake for the four groups of mice. c Liver, pancreas, spleen, and gWAT weight at the end of diet intervention. d Plasma
concentrations of triglycerides (TG) at the end of diet intervention. e Plasma concentrations of free fatty acids at the end of diet intervention. f Plasma
concentrations of total cholesterol (TC) at the end of diet intervention. All samples were measured in a single replicate. Data is represented as mean ± SEM.
*p < 0.05, effect of the diet; ***p < 0.001, effect of the diet; #p < 0.05, effect of the genotype; ##p < 0.01, effect of the genotype; ###p < 0.001, effect of the
genotype.
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steatosis (degree 0) (Fig. 3c). The remaining mice in this
group also had less severe liver injury when compared with
the WT HFD group (two Casp1/Casp11/NE/PR3 knockout
with steatosis degree 1 and one knockout mouse with stea-
tosis degree 2 versus three WT mice with steatosis degree 1,
four WT mice with steatosis degree 2, and one WT mouse
with steatosis degree 3) (Fig. 3c). Additionally, Casp1/
Casp11/NE/PR3 knockout mice had significantly less triglyc-
eride content in the liver when compared with WT controls
(Fig. 3d). These results suggest that Casp1/Casp11/NE/PR3
knockout mice were protected from developing diet-induced
liver steatosis.
Subsequently, we investigated mRNA expression
profiles of several inflammatory markers in liver
tissue. First, we assessed the mRNA levels of cyto-
kines that are processed by both caspase-1 and/or NE
and PR3, namely Il1β, Il18, and Il33 [25] (Fig. 3e),
but no differences between the mice groups were
observed. Next, the mRNA levels for the pro-
inflammatory cytokines Tnf and Il6 and the anti-
inflammatory marker Il1rn were measured (Fig. 3e).
No difference was observed for Tnf and Il6 between
the mice groups. This suggests that the HFD did not
induce pro-inflammatory cytokine transcription for
these markers.
Il1rn (the gene that encodes for IL-1 receptor antag-
onist-IL1-Ra) mRNA levels were significantly higher in
the WT mice that received a HFD when compared with
those in the other groups (2.15-fold change versus
0.66-fold change, p < 0.001), thereby confirming that
HFD induced a certain degree of hepatic inflammation.
We further tested markers that are also increased dur-
ing inflammation, including Cd68, Mcp1 (monocyte
chemoattractant protein-1), Tlr2 (toll-like receptor 2),
and Tlr4 (toll-like receptor 4) (Fig. 3e). Mcp1 mRNA
levels were significantly increased in both knockout
and WT mice that received a HFD when compared
with the LFD groups, thereby suggesting induction of
inflammation in the HFD groups. Altogether, no sig-
nificant differences in mRNA expression levels were
observed between WT and knockout for these inflam-
matory markers in liver tissue.
Casp1/Casp11/NE/PR3 Knockout Mice Display
Reduced Obesity-Induced Inflammation
During obesity, several changes occur in the adipose
tissue: adipocytes increase in number and size, pro-
inflammatory cells infiltrate the adipose tissue leading to
obesity-induced inflammation, and accumulating
macrophages surround dead adipocytes forming specific
complexes called crown-like structures (CLS) [26]. Interest-
ingly, Casp1/Casp11/NE/PR3 knockout mice fed a HFD had
smaller adipocytes (Fig. 4a), less adipose tissue per total body
weight (0.02 ± 0.009 g versus 0.04 ± 0.009 g; p < 0.0001)
(Fig. 4b), and significantly less CLS per adipocyte numbers
(0.09 ± 0.02 versus 0.14 ± 0.04; p = 0.0015) than WT mice
fed the same diet (Fig. 4c). These results show that Casp1/
Casp11/NE/PR3 knockout mice were protected from devel-
oping obesity-induced inflammation. Next, the adiponectin
and leptin plasma levels, two adipokines that are influenced
by the inflammatory status, were assessed [27]. We did not
observe any difference in the plasma concentration of adipo-
nectin and leptin between the groups (Fig. 4d, e). However,
plasma leptin concentration in the Casp1/Casp11/NE/PR3
knockout group that received a HFD tended to be higher
when compared with WT mice on the same diet (Fig. 4e).
Expression ofmRNAof inflammatorymarkerswas also
assessed in gWAT. Casp1/Casp11/NE/PR3 knockout mice
that received a HFD had significantly lower mRNA levels
of Il1rn,Mcp1,Cd68, and Tlr4 thanWTcontrols (Fig. 4f) and
were comparable with the levels of knockout mice fed a LFD.
However, no difference was observed between pro-
inflammatory cytokine levels of Il1β, Il18, Tnf, and Il6,
suggesting that the HFD did not induce pro-inflammatory
cytokine transcription for these markers.
Another consequence of adipose tissue inflammation
is the perturbation of the glycemic control and develop-
ment of insulin resistance [28]. In the last 2 weeks of the
diet intervention, we performed an insulin tolerance test
(ITT) and an oral glucose tolerance test (oGTT) but no
differences were observed between the four experimental
groups (Fig. 5a, b). At the end of the diet intervention,
glucose and insulin plasma concentrations were measured.
No differences in glucose levels were observed between
the groups (Fig. 5c). In contrast, insulin levels were signif-
icantly higher in the HFD groups when compared with the
LFD groups (0.91 ± 0.73 pg/mL versus 0.5 ± 0.47 pg/mL
for the knockout mice and 1.51 ± 0.6 pg/mL versus 0.85 ±
0.42 pg/mL for the WT mice; p < 0.01), as expected.
Moreover, insulin levels in Casp1/Casp11/NE/PR3 knock-
out mice fed a HFD were significantly lower than insulin
levels of WT mice receiving the same diet (0.91 ± 0.73 pg/
mL versus 1.51 ± 0.6 pg/mL; p < 0.01), suggesting that
Casp1/Casp11/NE/PR3 knockout mice might have better
glycemic control (Fig. 5d).
Altogether, these data show that Casp1/Casp11/NE/
PR3 knockout mice were protected for developing obesity-
induced adipose tissue inflammation while no clear differ-
ence was observed for the glycemic control.
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DISCUSSION
The aim of this study was to investigate whether IL-
1β activation pathways have a synergistic effect in pro-
moting development of diet-induced NAFLD. The results
show that mice lacking caspase-1 and the NSPs, PR3, and
NE are protected against high-fat diet–induced weight
gain, liver steatosis, and adipose tissue inflammation. Our
data are in line with previous observations. Our group has
previously shown that double knockout mice deficient in
NE/PR3 do gain weight after HFD intervention and
showed a certain degree of liver steatosis but significantly
less than WT controls fed the same diet. In addition, these
mice were protected against the development of adipose
tissue inflammation [18]. In contrast, Dixon et al. showed
that Caspase-1/11 double knockout mice developed HFD-
Fig. 3. Liver status at the end of the diet. WT, wild-type mice; 4ko, Casp1/Casp11/NE/PR3 knockout mice. a Representative images of liver histology in the
groups that received LFD at × 20magnification, respectively × 40magnification. bRepresentative image of liver histology in the groups that receivedHFD at
× 20 magnification, respectively × 40 magnification. cNumber of animals affected by different degrees of liver steatosis. d Triglyceride content of the liver in
the four groups of mice. All samples were measured in a single replicate. emRNA fold induction of several genes in the liver in the four groups of mice. All
samples were measured in duplicates. Data is represented as mean ± SEM. *p < 0.05, effect of the diet; ***p < 0.001, effect of the diet; #p < 0.05, effect of the
genotype; ###p < 0.001, effect of the genotype.
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Fig. 4. Adipose tissue inflammatory status. WT, wild-type mice; 4ko, Casp1/Casp11/NE/PR3 knockout mice. a Representative image of adipose tissue
histology inWTmice and Casp1/Casp11/NE/PR3 knockout mice that received a HFD intervention. b gWATweight reported to total body weight in the four
groups of mice. c Crown-like structures (CLS) count in gWAT in both WT and Casp1/Casp11/NE/PR3 knockout mice that received a HFD. d Adiponectin
concentration in plasma at the end of the diet intervention. All samples were measured in a single replicate. e Leptin concentration in plasma at the end of the
diet intervention. All samples were measured in a single replicate. f mRNA fold induction of several genes in the gWAT in the four groups of mice. All
samples were measured in duplicates. Data is represented as mean ± SEM. *p < 0.05, effect of the diet; **p < 0.01, effect of the diet; ***p < 0.001, effect of
the diet; ###p < 0.001, effect of the genotype.
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induced obesity and liver steatosis but were protected
against the development of liver inflammation and fibrosis
[10, 11]. In this study, we see additional protective effects
because Casp1/Casp11/NE/PR3 knockout mice do not
gain weight after HFD intervention. Mice did not devel-
oped liver steatosis and despite some gain of visceral
adipose tissue, they did not show signs of inflammation.
A change in the energy metabolism could also explain
why quadruple knockout mice fed a HFD were protected
from weight gain, liver steatosis, and gained less gWAT than
WT controls. Looking at single knockout models, we know
that caspase-1 knockout mice have higher fatty acid oxidation
rates and their adipocytes are more metabolically active when
compared with adipocytes from WT mice [12]. Also, NE
knockout mice have been described to have higher energy
expenditure rates, increased body temperature, and increased
fatty acid oxidation [16]. In line with these results, PR3/NE
knockout mice gained less weight, accumulated less trigly-
cerides in the liver than WT mice fed a HFD, and have
decreased mRNA expression of gene-encoding proteins in-
volved in lipogenesis and fatty acid uptake, suggesting a
better metabolic profile than WT mice [18]. Since our mouse
model is lacking all the genes mentioned above, it is likely
that these mice have also a more active basal metabolism and
have an improved control of lipid metabolism thanWTmice.
Future studies have to be performed in order to test this
hypothesis. For instance, the use of metabolic cages would
help to determine how Casp1/Casp11/NE/PR3 knockout
mice use energy and why they do not gain weight upon a
HFD intervention.
One important consequence of obesity is the develop-
ment of hypothalamic inflammation, which can further influ-
ence energy metabolism and the development of metabolic
disturbances [29]; hence, it would be interesting to assess
whether Casp1/Casp11/NE/PR3 knockout mice are protected
from developing hypothalamus inflammation in obesity,
which could also explain why these mice do not gain weight.
A limitation of our study is the fact that we did not use
single caspase-1, NE, and PR3 knockout mice as controls in
the diet intervention. This could have helped elucidate wheth-
er there is a cumulative protective effect against obesity-
induced metabolic disturbance. Another limitation is the fact
that the diet we used lead to the development of liver steatosis,
an early stage of NAFLD. Looking at the gene expression
profiles in both liver and adipose tissue, we do not see any
difference in levels of pro-inflammatory cytokines Il1β, Il18,
Fig. 5. Glucose homeostasis. WT, wild-type mice; 4ko, Casp1/Casp11/NE/PR3 knockout mice. a Glucose blood levels during the insulin tolerance test
(ITT). b Glucose blood levels during an oral glucose tolerance test. c Glucose concentration in plasma at the end of the diet intervention. d Insulin
concentration in plasma at the end of the diet intervention. All samples were measured in a single replicate. Data is represented as mean ± SEM. **p < 0.01,
effect of the diet; ##p < 0.01, effect of the genotype.
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Tnf, and Il6, but we do see some upregulation of the chemo-
kine Mcp1 in both quadruple knockout mice and WT that
received a HFD. Additionally, we see an upregulation of anti-
inflammatory cytokine gene Il1rn and surface marker genes
Cd68 and Tlr4 in the WT mice that received HFD. All these
results suggest that there is an induction of inflammation
during the HFD intervention but not strong enough to stim-
ulate pro-inflammatory cytokine production. A NASH-
inducing diet leads to the development of a more severe form
of inflammation and we should therefore be able to observe a
difference for Il1β and Il18 mRNA levels between Casp1/
Casp11/NE/PR3 knockout mice and WT mice.
An interesting experiment would be to investigate
whether blocking pharmacologically multiple IL-1β acti-
vation pathways during a HFD intervention is also able to
prevent liver damage. So far, we can conclude that mice
deficient for IL-1β activation pathways are protected
against NAFLD and liver steatosis.
CONCLUSION
In this study, we developed a unique mouse model,
which can be used to study both metabolic and inflamma-
tory diseases. Additionally, we observed that blocking IL-
1β activation pathways protects against HFD-induced obe-
sity and associated liver steatosis in mice. Further mecha-
nisms and therapeutic potential in patients with NAFLD
need to be explored.
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